Fluart Innovative Vaccines

This sponsor has funded 10 studies across 1 countries.

PAS funded by this sponsor.
EU PAS ID Status RMP requirement Title Protocol uploaded Results uploaded
7842 Finalised EU RMP category 3 Prospective non-interventional cohort study to assess safety and tolerability of Fluval AB 2014/2015 trivalent seasonal influenza vaccine in children,... Yes No
10350 Finalised EU RMP category 3 Prospective non-interventional cohort study to assess safety and tolerability of 3Fluart 2015/2016 trivalent seasonal influenza vaccine in children,... Yes No
15172 Finalised EU RMP category 3 Prospective non-interventional cohort study to assess safety and tolerability of 3Fluart 2016/2017 trivalent seasonal influenza vaccine in children,... Yes No
18936 Finalised EU RMP category 3 Prospective non-interventional cohort study to assess safety and tolerability of 3Fluart 2017/2018 trivalent seasonal influenza vaccine in children,... Yes No
24284 Finalised EU RMP category 3 Prospective non-interventional cohort study to assess safety and tolerability of 3Fluart 2018/2019 trivalent seasonal influenza vaccine in children,... Yes No
29839 Finalised EU RMP category 3 Prospective non-interventional cohort study to assess safety and tolerability of 3Fluart 2019/2020 trivalent seasonal influenza vaccine in children,... Yes No
35760 Finalised EU RMP category 3 Prospective non-interventional cohort study to assess safety and tolerability of 3Fluart 2020/2021 trivalent seasonal influenza vaccine in children,... No No
41178 Finalised EU RMP category 3 Prospective non-interventional cohort study to assess safety and tolerability of 3Fluart 2021/2022 trivalent seasonal influenza vaccine in children,... No No
47317 Finalised EU RMP category 3 Prospective non-interventional cohort study to assess safety and tolerability of 3Fluart 2022/2023 trivalent seasonal influenza vaccine in children,... No No
105039 Ongoing EU RMP category 3 Prospective non-interventional cohort study to assess safety and tolerability of 3Fluart 2023/2024 trivalent seasonal influenza vaccine in children,... No No

PAS by Risk Management Plan (RMP) requirement

Fluart Innovative Vaccines

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.